BaFin Warns Consumers About europecapitalmarkets.com

Germany's financial regulator, BaFin, has issued a warning regarding the website europecapitalmarkets.com. The website is suspected of offering banking and/or financial services without the required authorization from BaFin, posing a risk to consumers.

Allianz Global Life Designated Activity Company Address Change

Allianz Global Life Designated Activity Company's German branch has officially changed its business address. The notification, issued by BaFin on March 9, 2026, provides the previous and new addresses in Stuttgart.

BaFin Audits Gerresheimer AG Financial Statements

Germany's BaFin has expanded an audit of Gerresheimer AG's 2023/24 financial statements and initiated a new audit of its interim financial statements as of May 31, 2025. The audits are investigating potential misstatements in risk assessments, asset impairment, revenue recognition, lease liabilities, and development costs.

BaFin Warns of alijz(.)com Website and App

Germany's financial regulator, BaFin, has issued a warning regarding the website alijz(.)com, the app alijzspro, and associated WhatsApp groups. These entities are suspected of offering financial services without authorization, potentially misusing the identity of AL Konzept GmbH & Co. KG.

State v. Campos - Probation Revocation and Restitution Appeal

The Idaho Court of Appeals affirmed the revocation of Marlo Raymond Campos's probation but reversed and remanded the order for restitution. The original opinion dated November 14, 2025, was withdrawn and replaced by this substitute opinion filed on March 9, 2026.

State of Idaho v. Allen Paul Troup - Criminal Appeal

The Idaho Court of Appeals affirmed the district court's judgments of conviction and sentences for Allen Paul Troup for possession of a controlled substance. Troup appealed the denial of his motion to suppress and argued his sentence was excessive.

FDA Guidance: Flavored ENDS Premarket Applications

The FDA has issued guidance to assist with premarket tobacco product applications (PMTAs) for flavored electronic nicotine delivery systems (ENDS). This guidance, intended to improve submission and review efficiency, focuses on considerations related to youth risk. The document is non-binding and aims to inform potential future rulemaking.

FDA Draft Q&As on Biosimilar Development and BPCI Act

The FDA has issued a draft guidance document providing updated answers to common questions regarding biosimilar development and the Biologics Price Competition and Innovation Act (BPCI Act). This revision replaces a previous draft and focuses on specific Q&As related to the abbreviated licensure pathway for biological products.

FDA Q&A on Biosimilar Development and BPCI Act

The FDA has reissued its final guidance on biosimilar development and the BPCI Act, solely to withdraw three specific Q&As (I.8, I.10, and I.19). The agency is continuing to evaluate other Q&As for potential updates.

CMA Finalizes Water Company Bill Increases

The UK's Competition and Markets Authority (CMA) has issued a final decision on disputed price controls for five water companies, allowing an average bill increase of 2.2%. The CMA rejected 83% of the increases sought by the companies, granting £463 million in additional revenue, down from a provisional £556 million.